Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 6/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 4/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12210573 | 1.00 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1KDM4ECCR2HTT | |
| SCHEMBL10160076 | 1.00 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1KDM4ECCR2HTT | |
| SCHEMBL3397946 | 0.94 | CCR2 (0.41) | L3MBTL1ALDH1A1KDM4ECCR2HTT | |
| SCHEMBL12875886 | 0.94 | CCR2 (0.41) | L3MBTL1ALDH1A1KDM4ECCR2HTT | |
| SCHEMBL10160080 | 0.86 | — | — | |
| SCHEMBL6727176 | 0.86 | — | — | |
| SCHEMBL12210527 | 0.86 | — | — | |
| SCHEMBL6732580 | 0.80 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1KDM4ECCR2HTT | |
| SCHEMBL23835858 | 0.77 | CCR2 (0.43) | L3MBTL1ALDH1A1KDM4ECCR2HTT | |
| SCHEMBL8363330 | 0.77 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1KDM4ECCR2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | SYCHRONICITY PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023235880-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11834408-B2 | Compounds for the treatment of SARS | PURDUE RESEARCH FOUNDATION (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227695-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230543-A1 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023227698-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-6680331-B2 | ADMINISTERING DIETHYL LACTAMS SUCH AS 3,3-DIETHYL-2-PYRROLIDINONE FOR INDUCING ANESTHESIA OR CONSCIOUS SEDATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-01-20 | — | — | US | disclosed |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-04-24 | — | — | US | disclosed |
| WO-2003007940-A1 | LACTAM AND THIOLACTAM DERIVATIVES AS ANESTHETIC AND CONSCIOUS SEDATION AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-01-30 | — | — | WO | disclosed |
| US-6066666-A | OPTIONALLY N-SUBSTITUTED 3-MONO- AND DI-SUBSTITUTED 2-PYRROLIDINONES AND THIOLACTAM ANALOGS; TREAT SEIZURES, ANXIETY, AND ENHANCING 4-AMINOBUTYRIC ACID (GABA)-INDUCED CHLORIDE CURRENTS AT GABA RECEPTOR/IONOPHORE COMPLEX | WASHINGTON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5776959-A | Anticonvulsant and anxiolytic lactam and thiolactam derivatives | WASHINGTON UNIVERSITY (US) | 1998-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | L3MBTL1 888/4885ALDH1A1 1358/4885KDM4E 2621/4885 |
| US-20070225285-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | L3MBTL1 888/4885ALDH1A1 1358/4885KDM4E 2621/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | L3MBTL1 2934/4885ALDH1A1 2230/4885KDM4E 223/4885 |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | CNR1, CNR2, GABRA5 | L3MBTL1 4232/4885ALDH1A1 300/4885KDM4E 995/4885 |
| US-11834408-B2 | Compounds for the treatment of SARS | ACE2, SARS1, ACE | L3MBTL1 3075/4885ALDH1A1 2923/4885KDM4E 4049/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | L3MBTL1 3997/4885ALDH1A1 2465/4885KDM4E 414/4885 |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | GABRD, GABRE, CCT8 | L3MBTL1 1118/4885ALDH1A1 724/4885KDM4E 600/4885 |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | L3MBTL1 888/4885ALDH1A1 1358/4885KDM4E 2621/4885 |
| US-20240190837-A1 | CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS | CRY1, CRY2, HCCS | L3MBTL1 1954/4885ALDH1A1 2882/4885KDM4E 1254/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | L3MBTL1 4566/4885ALDH1A1 1806/4885KDM4E 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.